Compare BZ & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | GRFS |
|---|---|---|
| Founded | 2013 | 1940 |
| Country | China | Spain |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.0B |
| IPO Year | 2021 | 2008 |
| Metric | BZ | GRFS |
|---|---|---|
| Price | $14.92 | $7.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $23.00 | $10.15 |
| AVG Volume (30 Days) | ★ 8.7M | 354.2K |
| Earning Date | 05-21-2026 | 07-28-2022 |
| Dividend Yield | 1.24% | ★ 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.92 | $4.49 |
| Revenue Next Year | $12.78 | $6.42 |
| P/E Ratio | $22.61 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $6.96 |
| 52 Week High | $24.73 | $10.23 |
| Indicator | BZ | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 35.57 |
| Support Level | $12.95 | $7.33 |
| Resistance Level | $19.26 | $8.41 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.30 | -0.05 |
| Stochastic Oscillator | 5.61 | 5.76 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.